Real-time enrollment status for this psychosis associated with alzheimer's disease clinical trial
Current Status
Recruiting
Checked: August 27, 2026 at 11:51 AM UTC
| NCT Number | NCT06126224 |
| Recruiting Status | Recruiting |
| Condition | Psychosis Associated With Alzheimer's Disease |
| Phase | PHASE3 |
| Target Enrollment | 500 participants |
| Active Locations | 70 sites in the US |
| Sponsor | Karuna Therapeutics, Inc., a Bristol Myers Squibb company |
| Last Updated on CT.gov | July 30, 2026 (4 weeks ago) |
As of August 27, 2026: Clinical trial NCT06126224 is currently recruiting participants. This phase3 study for psychosis associated with alzheimer's disease is actively seeking new participants at 70 locations across the United States. The study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06126224 is actively recruiting participants as of August 27, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 70 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06126224 was last updated 4 weeks ago (July 30, 2026). HelloStudys verifies this status automatically.